CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.

Condition:   CLL Interventions:   Drug: ibrutinib, venetoclax, obinutuzumab;   Drug: ibrutinib, venetoclax Sponsors:   Stichting Hemato-Oncologie voor Volwassenen Nederland;   Nordic Lymphoma Group Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials